Company Analysis
Sign in

Myriad Genetics, Inc. (MYGN)

Nasdaq: MYGN · In Vitro & In Vivo Diagnostic Substances · Salt Lake City, UT · filing with the SEC since 1996
Full chart Alerts Compare
Grade6.0
◀ Past 6.7● Present 5.7▶ Future 5.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

121 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Myriad Genetics, Inc.’s names, not what it holds today.

Patents granted
121
118 utility, 3 design, 1976 to Dec 31, 2025
Granted in 2025
3
in the last year the record reads
Applications published
235
4 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Computer technology6
Biotechnology5
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Myriad Genetics, Inc. its own name
US, as the owner printed on each patent
121 granted
193 published
Myriad Genetics, Inc. its own name
named as the applicant on its applications, in US
0 granted
42 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 23, 202512,421,555Methods and materials for assessing homologous recombination deficiencyBiotechnologyMyriad Genetics, Inc.
Sep 9, 202512,410,478Hereditary cancer genesComputer technologyMyriad Genetics, Inc.
Feb 11, 202512,221,656Methods and materials for assessing homologous recombination deficiencyBiotechnologyMyriad Genetics, Inc.
Nov 22, 202211,505,832Method of using biomarkers and clinical variables for predicting chemotherapy benefitComputer technologyMyriad Genetics, Inc.
Jan 25, 202211,232,850Copy number variant callerComputer technologyMyriad Genetics, Inc.
Jan 18, 202211,225,685Methods and materials for assessing allelic imbalanceBiotechnologyMyriad Genetics, Inc.
Nov 16, 202111,174,519Method of treating cancerComputer technologyMyriad Genetics, Inc.
Nov 16, 202111,174,517Gene signatures for cancer prognosisBiotechnologyMyriad Genetics, Inc.
Aug 31, 202111,104,956Hereditary cancer genesComputer technologyMyriad Genetics, Inc.
Jun 1, 202111,021,752Genes and gene signatures for diagnosis and treatment of melanomaComputer technologyMyriad Genetics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Aug 7, 20252025/0250643METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITYComputer technologyMyriad Genetics, Inc.
Jul 10, 20252025/0223655METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCYBiotechnologyMyriad Genetics, Inc.
Jul 3, 20252025/0215509METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITYPharmaceuticalsMyriad Genetics, Inc.
Jun 5, 20252025/0179587METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCYBiotechnologyMyriad Genetics, Inc.
Nov 7, 20242024/0371481ARTIFICIAL INTELLIGENCE PREDICTIVE INTERACTIVITY BASED ON RECURSIVE DATA ANALYSISComputer technologyMyriad Genetics, Inc.
Sep 12, 20242024/0301500GLOBAL POLYGENIC RISK ASSESSMENT FOR BREAST CANCERBiotechnologyMyriad Genetics, Inc.
Aug 22, 20242024/0282407ELECTRONIC VARIANT CLASSIFICATIONComputer technologyMyriad Genetics, Inc.
Jun 6, 20242024/0182979CANCER BIOMARKERSComputer technologyMyriad Genetics, Inc.
Aug 17, 20232023/0260658POLYGENIC TRAIT PREDICTION USING LOCAL ANCESTRYComputer technologyMyriad Genetics, Inc.
Jul 6, 20232023/0212653METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPESBiotechnologyMyriad Genetics, Inc.
What it applied for, 2024 to 2025: Computer technology 4 · Biotechnology 3 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton MYGN · research, not advice